We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Novartis has signed a definitive agreement for the acquisition of all the outstanding shares of UK’s ocular gene therapy firm Gyroscope Therapeutics, in a deal worth up to $1.5bn.